Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS2465357 A
Type de publicationOctroi
Date de publication29 mars 1949
Date de dépôt14 août 1944
Date de priorité14 août 1944
Numéro de publicationUS 2465357 A, US 2465357A, US-A-2465357, US2465357 A, US2465357A
InventeursJohn T Correll
Cessionnaire d'origineUpjohn Co
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Therapeutic sponge and method of making
US 2465357 A
Images(3)
Previous page
Next page
Description  (Le texte OCR peut contenir des erreurs.)

Patented Mar. 29, 1949 NT orriclz THERAPEUTIC SPONGE AND METHOD OF MAKING John T. Correll, Kalamazoo, Mich, assignor to- The Upjohn Company company of Michigan Kalamazoo, Mich., a

No Drawing. Application August 14, 1944,

Serial No. 549,483

6 Claims.

This invention relates to a liquid-permeable, water-insoluble, gelatin sponge having the general physical characteristics of a sponge but being absorbable by animal bodies.

In various aspects of the practice of medicine and surgery it is desirable to insert into various This portions of the body a porous substance. may carry a therapeutic agent and hold such therapeutic agent in contact with certain tissues or organs. This porous substance should be reasonably soft when wet, have many fine interstices in order to hold a quantity of the therapeutic agent and to discharge it slowly, and/or act as an efiicient absorbative agent for free flowing fluids in a wound area such as blood. and exudates. It is preferably assimilable by the body in order that the incision into which it is placed need not be kept open. It is also desirable to have such a porous and assimilable substance for use as a surgical sponge in order that absorbativc packs may be left, if desired, in situ when closing an operative area, or to remove the danger present when a nonabsorbable sponge is inadvertently left in an incision. It is necessary that this substance be insoluble in water in order that it may be freely soaked in aqueous therapeutic solutions or will absorb blood and other body exudates without being affected thereby and without undue dissolution. It is further desirable that such sponge have physical properties that permit it to be readily cut into pieces which conform in size and shape to the contour of the area being treated.

Accordingly, the principal object of this inventionis to provide a sponge-like substance which has large numbers of small interstices that may be cut into convenient swabs or packs and is substantially insoluble in water, but which will be readily absorbable by the human body.

It is a further object of this invention to provide a sponge-like substance of the type mentioned which can be-manufactured in an economical manner.

It is a further object of this invention to provides. sponge-like substance of the type mentioned which can be manufacturedin aneconomical manner and which will be sterile upon arriving at the end ofitsmanufacturing process and willnot. require additional processing to insure a. sterile condition.

'Among the various problems arising in the field of medicine and surgery, there is particularly the case of minimizing the presence of blood around a surgical incision. The flow of blood is commonly stopped, or slowed by the application of a coagulating agent, such as thrombin. However, when the coagulating agentis merely poured into the incision, it impedes surgical D- erations nearly as much as" the} blood itself, or, if clotting is produced, the resulting clot quickly washes away. To prevent this, it is commonly applied by soaking small sponges in the coagulating'agent and placing them strategically within the incision.

This is effective but it presents the problem that, upon closin the wound, these 'nonabsorbable sponges must be removed, which usually results in reinstating hemorrhage. There is also the constant danger of inadvertently leaving a sponge within the incision.

It is desired, therefore, to eliminate these hazards by providing a sponge. which will be equally effective in the useas described and which will cause no inconvenience or danger if it is not removed from theincision. Also, it is frequently undesirable to remove a sponge because of the danger of starting hemorrhage. Sometimes these new sponges will be deliberately left within an incision in order to keep a constant supply of therapeutic agent at a selected point therein, as well as to preclude hemorrhage due to removal. It might also be desirable to have such a sponge whose rate of absorption into the body will be controllable so that the surgeon can select one which will remain in place the length of time which he desires. The process hereinafter disclosed by which my sponges are made can be easily controlled to vary the absorbability of the sponges as desired within considerable limits but without otherwise substantially-changing their properties.

In practicing my invention I first prepare an aqueous solution containing. 3-10% by weight of gelatin, preferably a skin gelatin, although other types, such as bone gelatin, may be employed, and these need not be highly purified. This is prepared at a relatively warm temperature, such as centigrade, allowed to cool .to-35?-40centigrade. Then I add a smallamount of formalin (40% aqueous. solution of formaldehyde), between 10.0 and 0.01 per cent based on the gelatin in solution, and incubate the resulting solution at slightly above room temperature} ('30-37 centigrade) for approximately two hours. The material is then beaten vigorously, for about. 5-15 minutes to produce a firm foam of from' i to 8 times the volume of the original solution. This is placed on a monel wire screen in a drying oven and large quantities of air at about 30 to 33 centigrade and 10% humidity are circulated through it. i This is continued until the foam is dry. When thoroughly dry, the foam is heated to a temperature of .approximately 140 centigrade, and allowed to remain there for about water at 80 centigrade, and cooled the resulting solution to 35 centigrade. Then I added 0.03 cubic centimeter of 40 per cent formalin and incubated the resulting mixture at 37 centigrade for about 2 hours, The solution was beaten vigorously for about minutes, at which time it had formed a firm foam with a volume of about 600 cubic centimeters. The foam was then placed on screens in a drying oven at 33 centigrade and large quantities of substantially dry air relative humidity) circulated through said oven at the same temperature. This was continued until the foam was thoroughly dry, whereupon it was heated to 140"-145 centigrade and kept at such temperature for three hours. quantities above mentioned, produced about 500 cubic centimeters of a dry, sterile, liquid-permeable, water insoluble gelatin sponge which was firm when dry but softened without dissolving when saturated with water. The dry material was suiliciently firm to be out easily by a small knife into whatever shapes and sizes were desired. The final heat treatment may be interrupted for packaging purposes, if desired, without disadvantage.

In practicing my invention, certain variations will be found at times convenient. In dissolvin the gelatin, any temperature of water will be usable provided only it is somewhat below the boiling point and hot enough to dissolve the gelatin with reasonable rapidity, The gelatin may be swelled with cold water before dissolving, if desired. The temperature to which it is cooled should be in the general region of 35 to 40 centigrade. The amount of formalin added will control the hardness of the sponge and its rate of absorption into the body. The more formalin the harder will be the sponge and the more slowly it will absorb. Also, the higher the temperature employed up to a scorching range, or the longer the heating-period employed in the final step of processing the-sponge, correspondingly influence -the,physical properties of the sponge and its rate of physiologic absorption. Optimal ranges for these influencing factors appear to be 0.03 to 0.3 cubic centimeter of formalin per 5 grams of gelatin and 100 grams of water, and heating of the dry sponge at 130 to 150 centigrade for from 2 to .5 hours, In beating the mixture, any time is to be used which is required to secure the foam but this will ordinarily be somewhat less than minutes. In drying the foam, any temperature which will not melt the foam at the particular humidity of the air employed will be acceptable, but I have found that temperatures above centigrade tend to melt the foam and lower temperatures require too much time for drying without providing any noticeable advantage. The relative humidity of the air should not exceed about 15 per cent. The step of heating the dried foam to 140-l45 centigrade increases the water insolubility and this temperature appears to be quite critical. An appreciably higher temperature will scorch the sponge and a temperature much below 130 centigrade will not yield a prod- This, for the uot with satisfactory physical properties. The use of formaldehyde or other hardening agent may be dispensed with and the foam hardened and insolubilized by the heating step alone. This step also makes the sponge sterile.

It is not known exactly how the sponge prepared by the above described method is absorbed by the body, but it is an observed fact that it is so absorbed in from ten to ninety days, depending upon the above-suggested variations in man ner of making the sponge, and no trace remains. The sponge is digested in vitro by enzymatic action, as by pepsin trypsin, and other proteolytic enzymes.

Having fully described my invention, I claim:

1. In the preparation of a gelatin sponge, the process: Preparing a 5 per cent by weight aqueous solution of gelatin at a temperature above room temperature but substantially below boiling, cooling same to approximately 35 centigrade, adding an amount of formalin between 0.01 and 10.0 cubic centimeters thereof per cubic centimeters of gelatin in solution, incubating the same at approximately 37 centigrade for about 2 hours, whipping the same until a foam is formed, drying the foam-at 33 centigrade and 10 per cent humidity, heating the dry foam for approximately three hours at a temperature of approximately 140 centigrade.

2. In the preparation of a gelatin foam, the process: preparing an aqueous solution of gelatin and bringing same to room temperature, adding formaldehyde thereto in an amount between 0.03 and 0.1 grams of 40% aqueous solution thereof per 5 grams of gelatin, whipping same until foam is formed, passing dry air at a temperature below about 35 centigrade through the foam to remove substantially all water therefrom, and heating the dry foam for approximately three hours at a temperature between and centigrade.

3. In the preparation of a gelatin foam, the process: mixing a limited amount of formaldehyde into an aqueous gelatin solution, beating said mixture until a foam is formed, removing substantially all of the water from said foam at a temperature below about 35 centigrade, and heating said dry foam for a substantial period of time at a temperature of at least about 130' and not substantially exceeding-about centirade.

4. In the preparation of a gelatin foam, the steps which include: forming an aqueous gelatin solution, beating said solution until a foam is formed, removing at a temperature below about 35 centigrade substantially all of the water from said foam. and heating said dry foam for a substantial period of time at a temperature above about 130 centigrade but not sufficiently elevated to cause scorching of the foam.

5. In the preparation of a gelatin sponge, the

- process which includes: preparing a 5 per cent by weight aqueous solution of gelatin at a temperature above room temperature but substantially below boiling, cooling same to approximately 35 centigrade, adding an amount of formalin between 0.01 and 1.0 cubic centimeter thereof per 100 cubic centimeters of gelatin solution, incubating the same at approximately 37 centigrade for about two hours, whipping the same until a foam is formed, drying the foam at a temperature below about 35 centigrade at about 10 per cent humidity, and heating the dry foam for approximately three hours at a temperature be- /tween about 130 and about 145 centigrade.

6. A water-permeable surgical sponge having a matrix consisting essentially of gelatin sponge UNITED STATES PATENTS hardened to the point of water insolubility and 5223 gffi a1 g characterized by substantially complete biological 1 985994 Holcomb 1935 absorbability in a living animal body in between 5 1999641 sharp 1935 abut ten and ninety days' 2 036 913 Brown $11111- Aor. '1 1936 JOHN T. CORRELL 2,141,760 Mould Dec. 27, 1938 FOREIGN PATENTS REFERENCES CITED 10 Number Country Date The following references are of record in the 265,968 Great Britain 1927 file of this patent: 674,775 Germany 1939

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US948845 *6 juil. 19098 févr. 1910Robert John CaldwellManufacture of filling or stuffing material.
US1985994 *13 janv. 19321 janv. 1935Johns ManvillePorous material and process of making the same
US1999641 *30 juil. 193230 avr. 1935Davis & SharpStrand for suture and other purposes and method of making the same
US2036913 *6 août 19327 avr. 1936Johns ManvilleSound absorbing article
US2141760 *1 août 193827 déc. 1938Tryit Novelty CompanyImitation drink
DE674775C *15 oct. 193521 avr. 1939Erik Christian BayerVerfahren zur Herstellung von Waerme- und Schallisolierplatten aus einer Loesung von tierischem Leim
GB265968A * Titre non disponible
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US2591927 *6 oct. 19488 avr. 1952Gladstone Sidney AObtaining tumor tissue specimen
US2712672 *28 janv. 195212 juil. 1955Calcagno LuigiProcess for preparing proteic sponges
US2731015 *16 mars 195317 janv. 1956Ohio Commw Eng CoArtificial sponge and method of making it
US2854978 *24 juil. 19567 oct. 1958Ortho Pharma CorpApplicator
US2899362 *11 août 1959 Hemostatic sponges and method of
US3121041 *20 juil. 196011 févr. 1964Olin MathiesonCapsule containing a pharmaceutically useful radioactive material
US3127313 *31 mars 1964 Method of making a radioactive
US3234091 *28 janv. 19638 févr. 1966Ciba Geigy CorpShaped medicaments and process for their manufacture
US3266054 *5 juil. 19639 août 1966Marcos JimenezMethod for treatment of hernias
US3300470 *4 oct. 196324 janv. 1967Swift & CoReaction products of protein with cyanamide under acidic conditions
US3451394 *4 avr. 196124 juin 1969Ethicon IncRadiating tanned and untanned collagen prosthesis with 5 to 25 megarads of ionizing radiation
US3516834 *18 mars 196623 juin 1970Eastman Kodak CoIonizing radiation sensitive photographic element comprising foamed gelatin-silver halide emulsion
US3799166 *22 mai 197226 mars 1974A MarsanStarch type gel seals for ostomy patients
US4186448 *21 nov. 19775 févr. 1980Brekke John HDevice and method for treating and healing a newly created bone void
US4265233 *6 avr. 19795 mai 1981Unitika Ltd.Material for wound healing
US4292972 *9 juil. 19806 oct. 1981E. R. Squibb & Sons, Inc.Medical sponges, gelatin
US4341207 *25 août 198027 juil. 1982Kingsdown Medical Consultants LimitedAir-permeable deodorizing, multilayer bandage; skin disorders
US4372314 *15 sept. 19808 févr. 1983Wall W HenryDental sponge
US4538603 *27 févr. 19853 sept. 1985E. R. Squibb & Sons, Inc.Less frequent changing required, easily removed
US4708869 *2 sept. 196924 nov. 1987The United States Of America As Represented By The Secretary Of The ArmyPersistent incapacitating chemical warfare composition and its use
US5039414 *1 août 198913 août 1991Mueller Marc BProcess for separating and/or recovering hydrocarbon oils from water using biodegradable absorbent sponges
US5795584 *7 févr. 199518 août 1998United States Surgical CorporationPost-surgical anti-adhesion device
US5904717 *9 janv. 199518 mai 1999Thm Biomedical, Inc.Method and device for reconstruction of articular cartilage
US5935594 *6 avr. 199810 août 1999Thm Biomedical, Inc.Employing a surfactant for efficiently incorporating a bioactive agent into the interstices of a porous and biodegradable polylactic acid body, wherein the bioactive agent is deposited on the internal surface
US5981825 *13 mai 19949 nov. 1999Thm Biomedical, Inc.Device and methods for in vivo culturing of diverse tissue cells
US6071301 *1 mai 19986 juin 2000Sub Q., Inc.Device and method for facilitating hemostasis of a biopsy tract
US6162192 *1 mai 199819 déc. 2000Sub Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US618349717 juin 19996 févr. 2001Sub-Q, Inc.Absorbable sponge with contrasting agent
US620032816 juin 199913 mars 2001Sub Q, IncorporatedDevice and method for facilitating hemostasis of a biopsy tract
US62647017 déc. 199824 juil. 2001Kensey Nash CorporationDevice and methods for in vivo culturing of diverse tissue cells
US63157535 mars 199913 nov. 2001Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US639938014 déc. 19984 juin 2002Anti-Cancer, Inc.An gelatinized pork skin collagen containing matix; for developing skin toxicity screening methods to prevent exposure of live animals to toxic substance
US64401516 juin 200027 août 2002Sub-Q, Inc.Device and method for facilitating hemostasis of a biopsy tract
US644015314 sept. 200127 août 2002Sub-Q, Inc.Device and method for facilitating hemostasis of a biopsy tract
US644753413 mars 200110 sept. 2002Sub-Q, Inc.Device and method for facilitating hemostasis of a biopsy tract
US65277347 août 20014 mars 2003Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US654073512 mai 20001 avr. 2003Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US654423613 oct. 20008 avr. 2003Sub-Q, IncorporatedDevice, system and method for improving delivery of hemostatic material
US661002616 mars 200126 août 2003Sub-Q, Inc.Method of hydrating a sponge material for delivery to a body
US684632024 sept. 200125 janv. 2005Sub-Q, Inc.Device and method for facilitating hemostasis of a biopsy tract
US684923212 mars 20021 févr. 2005Sub-Q, Inc.Exposing to a sufficient dose of E-beam irradiation to sterilize while retaining tensile strength and fluid absorbability
US68636808 nov. 20018 mars 2005Sub-Q, Inc.System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US696465814 févr. 200315 nov. 2005Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US698421918 mai 200110 janv. 2006Mark AshbyDepth and puncture control for blood vessel hemostasis system
US698462318 févr. 200410 janv. 2006Genetics, Institute Institute, LLC.Tendon-inducing compositions
US700844026 sept. 20027 mars 2006Sub-Q, Inc.System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US702574822 nov. 200211 avr. 2006Boston Scientific Scimed, Inc.Sheath based blood vessel puncture locator and depth indicator
US702948913 juin 200318 avr. 2006Sub-Q, Inc.System and method for delivering hemostasis promoting material to a blood vessel puncture site
US703732213 juin 20032 mai 2006Sub-Q, Inc.System and method for delivering hemostasis promoting material to a blood vessel puncture with a staging tube
US70373239 déc. 20032 mai 2006Sub-Q, Inc.Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US704871011 juil. 200023 mai 2006Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7074981 *2 mai 200211 juil. 2006Susanna Elizabeth ChalmersWound dressings and wound treatment compositions
US709100723 juin 200315 août 2006Genetics Institute, LlcComprises nucleotide sequences coding bone morphogenic and serine/threonine receptor proteins for for identifying modulators for use in prevention and treatment of bone and/or cartilage disorders
US717564625 mars 200213 févr. 2007Boston Scientific Scimed, Inc.Apparatus and method for percutaneous sealing of blood vessel punctures
US718939213 oct. 200013 mars 2007Genetics Institute, LlcOsteogenic protein with hyaluronic acid for drug delivery and tricalcium phosphate
US719243628 mai 200420 mars 2007Sub-Q, Inc.Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US720172525 sept. 200010 avr. 2007Sub-Q, Inc.Device and method for determining a depth of an incision
US721769127 mars 200315 mai 2007Genetics Institute, LlcAdministering BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein is encoded by a nucleic acid
US722658731 mai 20025 juin 2007WyethTo promote osteogenesis and therefore uses include fracture healing and repair and acceleration of fracture healing
US72647725 oct. 20044 sept. 2007Boston Scientific Scimed, Inc.Methods for sterilizing cross-linked gelatin compositions
US73007729 mars 200127 nov. 2007Genetics Institute, LlcBone morphogenic protein for use in the treatment of bone disorders; for use as wound healing agent
US732344518 févr. 200429 janv. 2008Genetics Institute, LlcMethods and compositions for healing and repair of articular cartilage
US733521912 juin 200326 févr. 2008Sub-Q, Inc.Hemostatic device including a capsule
US736505217 juin 200529 avr. 2008Genetics Institute, Llc.Tendon-inducing methods
US741375331 mai 200219 août 2008WyethContaining an effective amount of an effervescent agent.
US742924129 sept. 200530 sept. 2008Codman & Shurtleff, Inc.Dural graft and method of preparing the same
US761147913 déc. 20023 nov. 2009Sub-Q, Inc.System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US761856729 oct. 200417 nov. 2009Boston Scientific Scimed, Inc.Liquid permeable foam comprising radiopaque agent for use as tool in imaging biopsies and wokund puncture sites
US76219369 janv. 200424 nov. 2009Boston Scientific Scimed, Inc.Sheath-mounted arterial plug delivery device
US762213917 déc. 200724 nov. 2009Wyetha mixture of calcium phosphate as carriers and effervescent agents such as sodium bicarbonate, used for delivery of bone morphogenic proteins; treatment of bone disorders, bone regeneration, as well as tissue repair and reinforcement of bone fractures; implants and prosthetics
US762535224 juil. 20001 déc. 2009Sub-Q, Inc.Depth and puncture control for system for hemostasis of blood vessel
US767888528 févr. 200316 mars 2010Genetics Institute, LlcRecombinant bone morphogenetic protein heterodimers, compositions and methods of use
US769549212 juin 200313 avr. 2010Boston Scientific Scimed, Inc.Enhanced bleed back system
US775387229 janv. 200313 juil. 2010Boston Scientific Scimed, Inc.Device, system and method for improving delivery of hemostatic material
US777175510 sept. 200410 août 2010WyethFor therapy of bone disorders
US78750438 déc. 200425 janv. 2011Sub-Q, Inc.Cinching loop
US792303128 janv. 200512 avr. 2011Ferrosan Medical Devices A/SHaemostatic sprays and compositions
US792343123 déc. 200212 avr. 2011Ferrosan Medical Devices A/SHaemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US795528811 déc. 20037 juin 2011Ferrosan Medical Devices A/SGelatine-based materials as swabs
US795535312 juin 20037 juin 2011Sub-Q, Inc.Dissolvable closure device
US800313323 sept. 200923 août 2011Wyeth LlcCalcium phosphate delivery vehicles for osteoinductive proteins
US80216847 juil. 200520 sept. 2011Ferrosan Medical Devices A/SHaemostatic composition comprising hyaluronic acid
US803959121 avr. 200918 oct. 2011Codman & Shurtleff, Inc.Flowable collagen material for dural closure
US805074121 déc. 20041 nov. 2011Boston Scientific Scimed, Inc.Device and method for facilitating hemostasis of a biopsy tract
US81876254 févr. 200229 mai 2012Boston Scientific Scimed, Inc.Cross-linked gelatin composition comprising a wetting agent
US82833207 avr. 20119 oct. 2012Ferrosan Medical Devices A/SHaemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis
US831782112 juin 200327 nov. 2012Boston Scientific Scimed, Inc.Release mechanism
US841455011 avr. 20079 avr. 2013Lexion Medical, LlcSystem and method to vent gas from a body cavity
US85070082 juil. 201013 août 2013Etex CorporationInjectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
US852427022 mai 20123 sept. 2013Boston Scientific Scimed, Inc.Cross-linked gelatin composition coated with a wetting agent
US85856463 mars 200819 nov. 2013Lexion Medical, LlcSystem and method to vent gas from a body cavity
US86087158 avr. 201317 déc. 2013Lexion Medical, LlcSystem and method to vent gas from a body cavity
US862384226 sept. 20077 janv. 2014Hemostasis, LlcHemostatic agent and method
US864283127 févr. 20094 févr. 2014Ferrosan Medical Devices A/SDevice for promotion of hemostasis and/or wound healing
US869670227 oct. 200915 avr. 2014Boston Scientific Scimed, Inc.Sheath-mounted arterial plug delivery device
US879571022 août 20085 août 2014Codman & Shurtleff, Inc.Collagen device and method of preparing the same
US882191815 août 20132 sept. 2014Boston Scientific Scimed Inc.Cross-linked gelatin composition comprising a wetting agent
US20110014290 *22 sept. 201020 janv. 2011Boston Scientific Scimed, Inc.System and method for facilitating hemostasis with an absorbable sponge
DE950751C *1 févr. 195218 oct. 1956Behringwerke AgVerfahren zur Herstellung spontan und schnell saugender Tampons aus resorbierbarem Material
DE1105112B *10 août 195420 avr. 1961Dr Luigi CalcagnoVerfahren zur Herstellung von Gelatineschwaemmen
EP0044624A1 *23 juin 198127 janv. 1982E.R. Squibb & Sons, Inc.Lyophilized hydrocolloid foam
WO2000078228A1 *16 juin 200028 déc. 2000Sub QAbsorbable sponge with contrasting agent
WO2002072128A1 *14 févr. 200219 sept. 2002Sub Q IncCross-linked gelatin composition comprising a wetting agent
WO2004053051A2 *11 déc. 200324 juin 2004Ferrosan AsGelatine-based materials as swabs
WO2011144916A17 avr. 201124 nov. 2011Fujifilm Manufacturing Europe BvHemostatic compositions
Classifications
Classification aux États-Unis106/122, 604/369, 424/426, 604/368, 424/444, 530/354, 106/156.3
Classification internationaleC08J9/30, A61L15/64, A61L15/32, A61L15/42
Classification coopérativeC08J2389/00, A61L2400/04, C08J9/30, A61L24/0036, A61L24/104
Classification européenneA61L24/00H8, A61L24/10E, C08J9/30